NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
3/8 — Basic
PYRIDOSTIGMINE BROMIDE (pyridostigmine bromide) by Novartis is clinical pharmacology regonol (pyridostigmine bromide injection, usp) an analogue of neostigmine, facilitates the transmission of impulses across the myoneural junction by inhibiting the destruction of acetylcholine by cholinesterase. First approved in 2024.
Drug data last refreshed 13h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pyridostigmine bromide is an anticholinesterase agent (REGONOL brand) administered orally as an extended-release tablet that facilitates neuromuscular transmission by inhibiting acetylcholine destruction at the myoneural junction. It is primarily used to reverse neuromuscular blockade from nondepolarizing muscle relaxants during anesthesia and has a longer duration of action with fewer side effects than neostigmine. The drug works by preserving acetylcholine levels, enabling continued muscle contraction despite the presence of neuromuscular blocking agents.
Growth11.6 years to LOE
Recent 2024 approval positions this as a growth-stage product with expanding market penetration; commercial teams are scaling field presence and provider education.
Mechanism of Action
CLINICAL PHARMACOLOGY REGONOL (pyridostigmine bromide injection, USP) an analogue of neostigmine, facilitates the transmission of impulses across the myoneural junction by inhibiting the destruction of acetylcholine by cholinesterase. Currently available data indicate that pyridostigmine may have a…
Worked on PYRIDOSTIGMINE BROMIDE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.